Selvigaltin (GB1211), an orally accessible small molecule galectin-3 inhibitor developed being a therapy for liver fibrosis and cirrhosis, was evaluated to assess the influence of hepatic impairment on its pharmacokinetics and safety to handle regulatory prerequisites. Participants were also excluded if that they had clinically sizeable abnormalities in electrocardiogram (ECG) https://selvigaltingalectin-3inhi39124.jts-blog.com/37981021/the-5-second-trick-for-selvigaltin-galectin-3-inhibitor